Laura Michael

Nov 12, 2023 | jamanetwork.com | Steven Nissen |Kathy E. Wolski |Laura Michael

Key PointsQuestion  What is the safety and tolerability of lepodisiran, which is a short interfering RNA directed at hepatic production of apolipoprotein(a), and the effect on lipoprotein(a) serum concentrations at doses from 4 mg to 608 mg through 336 days (48 weeks) of follow-up? Findings  The trial enrolled 48 participants without cardiovascular disease and with lipoprotein(a) concentrations of 75 nmol/L or greater (or ≥30 mg/dL). A single serious adverse event occurred.